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Background: It has been repetitively shown that the transcription factors DLX5 and DLX6 are 
drastically downregulated in endometriotic lesions when compared with eutopic endometrium. 
These findings suggest that regulatory cascades involving DLX5/6 might be at the origin of endo-
metriosis symptoms such as chronic pelvic pain (CPP). We have shown that inactivation of Dlx5 
and Dlx5/6 in the mouse uterus results in an endometrial phenotype reminiscent of endometriosis.
Methods: We focused on genes that present a similar deregulation in endometriosis and in 
Dlx5/6-null mice in search of new endometriosis targets.
Results: We confirmed a strong reduction of DLX5 expression in endometriosis implants. We 
identified a signature of 30 genes similarly deregulated in human endometriosis implants and 
in Dlx5/6-null mouse uteri, reinforcing the notion that the downregulation of Dlx5/6 is an early 
event in the progress of endometriosis. CACNA2D3, a component of the α2δ family of voltage-
dependent calcium channel complex, was strongly overexpressed both in mutant mouse uteri 
and in endometriosis implants, were also CACNA2D1 and CACNA2D2, other members of the 
α2δ family involved in nociception, are upregulated.
Conclusion: Comparative analysis of gene expression signatures from endometriosis and 
mouse models showed that calcium channel subunits α2δ involved in nociception can be 
targets for the treatment of endometriosis-associated pain. CACNA2D3 has been associated 
with pain sensitization and heat nociception in animal models. In patients, CACNA2D3 vari-
ants were associated with reduced sensitivity to acute noxious stimuli. As α2δs were targets 
of gabapentinoid analgesics, the results suggested the use of these drugs for the treatment of 
endometriosis-associated pain. Indeed, recent small-scale clinical studies have shown that 
gabapentin could be effective in women with CPP. The findings of this study reinforce the 
need for a large definitive trial.
Keywords: endometriosis, gabapentin, CACNA2D3, Dlx5, pain
Introduction
Endometriosis is characterized by the growth of endometrial-like tissue consisting 
of glandular tissue and stroma outside the uterine cavity in localized and innervated 
implants. Remarkably, endometriosis lesions present histopathological and physiologi-
cal responses that are similar to those of the endometrium. Endometriosis patients 
frequently experience various pain symptoms including chronic pelvic pain (CPP), 
dysmenorrhea, dyspareunia, and dyschezia,1 which often result in severe personal, 
social, and economic difficulties. Treatment of endometriosis-associated pain is dif-
ficult due to its poorly understood pathophysiology, complex clinical presentation, and 
natural history. Endometriosis is generally treated by surgical intervention, analgesic 
treatment, or hormonal treatment suppressing cyclic ovarian hormone production and 
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reducing or eliminating menses.2 Current therapies present, 
however, limited efficacy on endometriosis pain, due to high 
rates of symptom recurrence, and significant side-effects.3,4
Dlx genes comprise a highly conserved family of 
homeobox genes. Dlx5 and Dlx6 (Dlx5/6) are expressed 
in GABAergic neurons of the brain including delta opioid 
receptor-positive GABAergic neurons that are involved 
in the regulation of chronic pain.5 Besides early roles in 
neuronogenesis and limb and craniofacial patterning during 
embryogenesis,6 Dlx5/6 are also involved in the differentia-
tion of steroidogenic tissues including Leydig cells in the 
testis7 and theca and granulosa cells in the ovary.8 DLX5 and 
DLX6 are expressed in glandular and lining epithelial cells 
of mouse and human endometrium9 where their expression 
is upregulated during the secretory phase10 of the cycle. By 
targeted inactivation of Dlx5/6 in the mouse uterus, we have 
demonstrated their central role for uterine adenogenesis and 
fertility.9
It has been repeatedly shown that the expression of 
DLX5 and DLX6 is strongly downregulated in endometriotic 
lesions compared to eutopic endometrium.11–14 Endometriosis 
implants and Dlx5/6 mutant mouse uteri have, therefore, in 
common a very low level of Dlx5 expression. Furthermore, 
Dlx5/6-null endometrial epithelia present a histological 
appearance reminiscent of that found in endometriosis 
implants with very few glands and a cuboidal lining epithe-
lium that locally tends to desquamate.9 The histological and 
molecular similarities between endometriosis implants and 
Dlx5/6-null mouse uteri have prompted our suggestion that 
the downregulation of DLX5/6 could be an early event in 
the progress of endometriosis and that inactivation of these 
genes in the mouse uterus could constitute a model of the 
human pathology.9
Here, we show that Dlx5/6-null mouse uteri and ectopic 
human endometrium share 30 deregulated genes confirming 
the these mice can be considered a model of the disease; we 
suggest that these 30 shared genes are a new, more focused, 
molecular signature of endometriosis. We focus our atten-
tion on CACNA2D3, an overexpressed gene that has an 
evolutionary-conserved role in nociception.15 CACNA2D1, 
CACNA2D2, and CACNA2D3 constitute the α2δ gene family 
of glycosylphosphatidyl inositol (GPI)-anchored transmem-
brane voltage-gated calcium channel (VGCC)-associated 
subunits. During membrane depolarization, VGCCs permit 
Ca2 influx, contributing to cell depolarization and func-
tioning as secondary messengers regulating key neuronal 
mechanisms including gene expression and neurotransmitter 
release. VGCCs are involved in generating neuropathic pain 
and are targets of gabapentinoids.16 Remarkably, CACNA2D1 
to 3 are significantly increased in endometriosis implants12,13 
and should therefore be considered as targets for the treatment 
of endometriotic pain.
Methods
Endometrial biopsies
A total of 37 ovarian endometriosis and 12 normal endo-
metrium samples were selected from the formalin-fixed, 
paraffin- embedded tissue collection of the Division of 
 Anatomic Pathology, Department of Surgical Science and 
Integrated Diagnostics, University of Genoa, Italy. All 
patients signed an informed consent under local institutional 
review board-approved protocols for research purposes deal-
ing with the archived endometriosis tissues in the pathology 
department. Informed consents are available on request (from 
LM). The Regional Liguria Ethical Committee for medical 
research approved the use of archive human samples.
Animals
Procedures involving animals were conducted in accordance 
with the directives of the European Community (council 
directive 86/609) and the French Agriculture Ministry 
(council directive 87-848, October 19, 1987, permissions 
00782 to GL). The project was reviewed and approved by 
the “Cuvier” ethical committee of the Muséum National 
d’Histoire Naturelle and transmitted to the French Ministry 
of Agriculture. Mice were housed in specific pathogen-free 
and light-, temperature- (21°C), and humidity (50–60% rela-
tive humidity)-controlled conditions. Food and water were 
available ad libitum. Conditional Dlx5/6flox/flox mutants were 
generated as described.9 To obtain Pgrcre/+;Dlx5/6flox/flox mice, 
we crossed Pgrcre/+;Dlx5/6flox/+ males with Dlx5/6flox/flox females.
Immunohistochemistry
Fixed tissue samples were embedded in paraffin, and 5 mm 
thick sections were cut. Slides were dewaxed in xylol and re-
hydrated in ethanol solutions. Antigen exposure was achieved 
by submerging slides in sodium citrate 0.01 M, pH 6.0 
(Sigma-Aldrich Co., St Louis, MO, USA) and heating at 90°C 
with pressure in a 2100-Retriever device (Prestige Medical, 
Northridge CA, USA). Endogenous peroxidase activity was 
quenched by incubation with 3% (vol/vol) H
2
O
2
 in methanol 
(Merck Millipore, Billerica, MA, USA) or with peroxidase-
blocking solution from Dako EnVision + System HRP kit 
(K4011; Agilent Technologies, Santa Clara, CA, USA) for 
30 minutes. Tissue sections were then blocked with 5% (wt/
vol) bovine serum albumin (BSA) (Sigma-Aldrich Co.) or 
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10% of fetal calf serum (FCS) in PBS at room temperature for 
2 hours and then incubated with anti-DLX5 (NBP1-19547; 
Novus Biologicals, Littleton, CO, USA) polyclonal rabbit pri-
mary antibody at 1/200 dilution, or anti-CACNA2D3 at 1/250 
dilution (NBP1-30557; Novus Biologicals), or anti-CBS at 
1/400 dilution (1478-1-AP; Proteintech, Manchester, UK), or 
anti-LTBP2 at 1/250 dilution (17708-1-AP; Proteintech, UK), 
or anti-GJB3 at 1/50 dilution (12880-1-AP; Proteintech, UK), 
or anti-NOXA1 at 1/100 dilution (CUSABIO, Huston, TX, 
USA), or anti-KIAA1324 at 1/200 dilution (Thermo Fisher 
Scientific, Waltham, MA, USA) in PBS 5% FCS overnight at 
4°C in a humidified chamber. Normal rabbit IgGs were used 
as negative control. Next, slides were washed with PBS and 
detection of the primary antibody was achieved by using the 
Histostain-SP Broad Spectrum kit (Thermo Fisher Scientific) 
or goat antirabbit antibody linked to horseradish peroxidase 
(Dako EnVision + System HRP kit; K4011). Counterstain 
was done using the hematoxylin-stabilized solution 1/5 (RAL 
Diagnostics, Martillac, France) according to standard pro-
cedures. Images were visualized under an Olympus BX-51 
microscope and captured using the Image-Pro Plus v.6.2 
software (Media Cybernetics, Rockville, MD, USA).
RNAseq
RNA library preparation was carried out according to the 
Illumina TruSeq Stranded Total RNA Sample Prep protocol, 
following Ribo-Zero Gold Deplete procedure (Illumina, San 
Diego, CA, USA). From a total amount of 1.5 µg of total 
RNA, both cytoplasmic RNA and mitochondrial ribosomal 
RNA (rRNA) were removed using specific biotinylated 
oligos and Ribo-Zero rRNA removal beads. RNA, purified 
from uteri of three PgrCre/+;Dlx5/6flox/flox and three Dlx5/6flox/flox 
mice at PN25, was fragmented by the addition of divalent 
cations and the incubation at 94°C for 4 minutes. The first 
cDNA strand was synthesized using random primers and 
a reverse transcriptase. DNA polymerase I synthesized 
the second cDNA strand and generated blunt-ended ds 
cDNA, while RNase H removed the RNA template. An 
A nucleotide was added to the 3′ ends, followed by the 
ligation of multiple indexing adapters that are required for 
the pooling and the hybridization with the flow cell. These 
DNA products were purified, and only those having adapter 
molecules on both ends were enriched with PCR by using 
a Cocktail Primer that anneals specifically to the adapt-
ers. The obtained libraries were validated by Bioanalyzer 
(Agilent DNA 1000; Agilent Technologies) and pooled and 
sequenced using the Illumina HiSeq 2000 sequencing sys-
tem. The global quality of each library was checked using 
the FastQC  software (http://www.bioinformatics.babraham.
ac.uk/projects/fastqc/). To reduce any PCR amplification 
bias, duplicated reads were removed before the duplicated 
reads before the mapping based on a 100% sequence iden-
tity between reads. Then, five nucleotides were trimmed 
at both 5′ and 3′ ends of all remnant reads using FASTX-
Toolkit v0.0.14 (http://hannonlab.cshl.edu/fastx_toolkit/
index.html). Reads were mapped against the mouse mm10 
genome (Version GRCm38.p3) using the TopHat2 software 
v2.0.1017 with default parameters. Only uniquely mapped 
reads were kept and were counted on genes’ exons using 
the HTSeq-count software v0.6.1p118 with “union” mode 
using the Mus musculus Ensembl annotation (release 79). 
Only coding and expressed genes were considered. “R” 
package DESeq2 v1.8.019 was used for statistical analyses 
to determine differential gene expression levels (cutoff: 
adjusted P-value ≤0.1). Samples’ homogeneity was checked 
realizing a principal component analysis with “R” package 
FactoMineR, following which, one mutant mouse was not 
considered for further analysis.
To identify mouse and human orthologs, we used the 
BioMart tool, provided by Ensembl, Heidelberg, Germany.
From 424 genes differentially expressed in Pgrcre/+; 
Dlx5/6flox/flox mice, we found 391 human orthologs, which 
have been used for comparison.
Quantitative real-time PCR (qPCR)
Total RNA was isolated from five mouse uterine samples 
per group using an RNeasy Mini Kit (Qiagen NV, Venlo, 
the Netherlands) according the manufacturer’s instructions. 
On-Column Deoxyribonuclease I (Hoffman-La Roche 
Ltd., Basel, Switzerland) digestion was incorporated into 
an RNA isolation procedure to remove potential genomic 
DNA contamination. RNA concentration and the ratio of the 
absorbance at 260 and 280 nm were measured using a Nano-
Drop 2000 spectrophotometer (Thermo Fisher Scientific). 
Reverse transcription was carried out using 600 or 200 ng 
total RNA and Primscript (Ozyme) reverse transcriptase to 
obtain cDNA. qPCR was performed using the QuantStudio 
6 Flex Real-Time PCR System (Thermo Fisher Scientific). 
The PCR program consisted of 95°C for 10 minutes, 40 
cycles 95°C for 15 seconds, and 60°C for 10 minutes. Rela-
tive gene expression was measured using SYBR Green mix 
gene expression assays (Thermo Fisher Scientific). Primers 
utilized are shown in Table 1. To measure the relative amount 
of PCR products, the Ct geometric mean of Sdha and Hprt1, 
was subtracted from the Ct of genes of interest to derive ∆Ct. 
The ∆Ct of mutant animals was compared with ∆Ct of control 
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animals, and the difference was assigned as ∆∆Ct. The fold 
change between two samples was then calculated as 2-∆∆Ct.
Statistical analysis
The Mann–Whitney unpaired test was conducted using 
Prism (GraphPad Software, Inc., La Jolla, CA, USA) to 
calculate the differences between groups of five independent 
measurements. All values are expressed as mean ± SEM of 
combined data from replicate experiments. Values P<0.05 
were considered statistically significant.
Results
DLX5 distribution in normal 
endometrium and in endometriosis
First, we analyzed the distribution of DLX5 in normal 
endometrium from various stages of the menstrual cycle 
by immunohistochemistry (Figure 1A–B′). DLX5 protein 
is prevalently present in endometrial glandular and luminal 
epithelial cells. The intracellular distribution of DLX5 varies 
at different phases of the cycle: during the proliferative phase, 
DLX5 is detected both in the nucleus and in the cytoplasm 
(Figure 1A and A′), while in the secretory phase, DLX5 is 
predominantly present in the cytoplasm (Figure 1B and B′) 
where it displays a polarized distribution mostly toward the 
luminal and basal aspects of the cells.
Most endometriotic lesions (Figure 1C–D′) present very 
few glands with a very large lumen covered by an atypical 
noncolumnar epithelium, which does not present a uniform 
phenotype even between different epithelial regions from the 
same patient (eg, the two facing epithelia in Figure 1D′). In 
certain regions, epithelial cells are large and noncohesive 
(Figure 1C′ and D′), while in other territories, they display 
a flattened phenotype with very little cytoplasm (Figure 1D′ 
and E′); cells are almost invariably ciliated. The intensity of 
anti-DLX5 staining is generally low or at the limit of detec-
tion (Figure 1C–D′), but occasionally (Figure 1E and E′), a 
clear signal can be detected in the cytoplasm and in peri-
nuclear regions, while nuclei are mostly negative; frequently, 
epithelia are constituted by a mixture of DLX5-positive and 
DLX5-negative (arrows in Figure 1E′) cells.
Table 1 PCR primers used in this study
Genes Forward primer Reverse primer Length (bp)
NOXA1 CCGCTGGCTAGGATGTACTT CAGCTGGAAATTGGCCACTC 150
DMRTA1 CCCAACTTTCGAGGTTTTCCA CCCAGAGAATGGTGATGAGTGTT 126
KIAA1324 TAGACCTCCACAGTCAGTGGT GCATTCTCTTCGATGGTGTAGG 198
SLC27A2 TCCTCCAAGATGTGCGGTACT TAGGTGAGCGTCTCGTCTCG 166
GABRP ATGAGCTACAGCCTCTATTTGGC ACCACCGAAATTGGGCCTG 174
SAPCD2 GGGCTCTTCTCAGTGTGACA ACCTTCTTCAGCACTTGTGC 106
PLCH1 GGCTCGTTCGCCTCTTTTAC CTGCCCTCGGTGACTTTGTAG 118
GJB3 GCTCCAAGACCTATTGAGTGGC GCCTGGTGTTACAGTCAAAGTC 155
DPP6 CAGAGGCAAAGTGGATAAGCA TCAACATTCCGCAGTATGACAC 76
OSCP1 TGCTTTACGTCCTAGACCAGC GGTTTGAACAGTTCGTCCATGA 124
JAZF1 GCCGAGAACAGGAATCTCTGA GTAAGGCTGCCACTGCTATGT 118
CBS GGGACAAGGATCGAGTCTGGA AGCACTGTGTGATAATGTGGG 100
NAIP5 GCAGTCTCTCGAGGTCTCAG CACACAGTTCTTTCAGGCCC 89
EMB TGAGGGCGATCCCACAGAT CCGTCACTGAGATATTACAGCTC 107
CLIP4 AGAAGGTCGATGTAGCCCAC TCCGCTACAGTTTTCGGTTC 124
PIK3AP1 GTCCCGGATGCCTCTTTCTC CACAAGTCATTTCCTGCCAGT 241
LAPTM5 ACATCGAATTGCCAGCGTAC CAGCTGCAGTGTCATCAAGG 80
CTGF GGGCCTCTTCTGCGATTTC ATCCAGGCAAGTGCATTGGTA 151
NAIP2 TGTGCTCTCAGTCCTTCCTG AAGCACAGTCATGAGAGGCT 184
CACNA2D3 AAGAAATCGACGGTCTCCAAC GGTCATTGGGGGCTAAGATGAA 237
LTBP2 AACAGCACCAACCACTGTATC CCTGGCATTCTGAGGGTCAAA 159
TNS3 ACATGCACTTCACCAACGTC CTGAGAAACTGCACGTACCG 130
RAB20 GCAGTGGCGTTCCTTCAAC GGAGCCCAGACCATGAAACT 70
SYTL2 TCAAAAAGCCGACCAAGAACC AGGCACTGTGGAAATTCCTGG 61
LBH CTGCTCTGACTATCTGAGATCGG CGGTCAAAGTCTGATGGGTCC 135
ENC1 CTGTTTCATAAGTCCTCCTACGC CACCACTGAACATGGCTTCG 169
MANBA GACTGTCCCCGGCTATGTG AATTCCGTGCTGTAGGTCCA 126
GALM CTGCACGATCACTGCTCTG CACTGCTCCAAAGTAGGGCTG 115
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A shared genetic signature between 
Dlx5/6-null mouse uteri and 
endometriosis implants
DLX5 and DLX6 are between the most downregulated 
genes in endometriosis implants,11–13 and their inactiva-
tion in the mouse uterus results in an endometriosis-like 
 phenotype.9 To better investigate the apparent similarity 
between endometriotic implants and mouse Dlx5/6-null 
uteri, we have compared the RNAseq profiles of genes 
deregulated in the mutant mouse uterus with those reported 
in four independent studies in which the expression pro-
file of endometriosis implants was compared with that of 
eutopic endometrium.12–14,20 Hawkins et al12 described 2083 
deregulated genes in endometriotic lesions; among this set 
of genes, 997 genes are underexpressed and 1086 genes are 
overexpressed. Several of these genes were also identified 
in the three other studies, which we have considered,13,14,20 
providing a shared database to identify potential therapeutic 
targets. Comparison of Dlx5/6-mouse mutant uterus RNAseq 
dataset with the human datasets permits identifying 30 genes 
that present a common deregulation in the mouse and in 
endometriotic lesions: 13 downregulated and 17 upregulated 
genes (Table 2). If indeed the downregulation of Dlx5/6 is an 
early event in endometriosis progression, this set of 30 genes 
could well constitute a more focused molecular signature of 
endometriosis implants (Figure 2).
Validation by qPCR
In a first round of validation, we analyzed, by qPCR, the effect 
of Dlx5/6 inactivation on the expression levels of 28 of the 30 
genes identified by RNAseq comparison (Figure 3A and B). In 
all cases, the trend of variation occurred in the direction pre-
dicted by RNAseq either up (Figure 3A) or down (Figure 3B); 
however, due to high individual variability, the variation 
reached a level of significance for only 12 genes. Between the 
upregulated genes, the expression of CACNA2D3 and CBS 
was, respectively, increased six and seven times. CACNA2D3 
together with CACNA2D1 and CACNA2D2 constitutes the 
family of α2δ VGCC subunits involved in nociception. In 
Dlx5/6-null mouse uteri, the expression levels of CACNA2D1 
and CACNA2D2 were not significantly changed after RNAseq 
analysis and were not further analyzed.
Remarkably, the expression of each of these three genes 
is significantly increased in endometriosis implants (Data 
Set Records GDS2835 and GDS3975).12,13 Interestingly, 
the cystathionine-b-synthase (CBS) gene has been already 
shown to be hypomethylated and upregulated in endome-
triosis lesions.21
Altered pattern of gene expression in 
human endometriosis
To validate the upregulation in endometriosis of the most 
significantly affected genes, we performed immunohis-
tolocalization on section from normal endometrium and 
Figure 1 Immunohistolocalization of DLX5 in normal endometrium and ovarian 
endometriosis.
Notes: In healthy endometrium, DLX5 protein is detected in glandular epithelia 
(A, A′, B, and B′). During the proliferative phase (A and A′), the protein is present 
both in epithelial nuclei and in the cytoplasm. In contrast, during the secretory phase 
(B and B′) DLX5 presents a polarized distribution in the cytoplasm and is virtually 
absent from the nuclei. In ovarian endometriosis implants (C–E′), the expression 
of DLX5 is more variable. Most of the implants present very few glands with a 
very large lumen and a thin cuboidal epithelia, which is in general constituted by a 
mixture of DLX5-positive and DLX5-negative (arrows in E′) cells. Scale bar: (A and 
B) 250 µm; (C–E) 125 µm; and (A′, B′, C′, D′, and E′) 25 µm.
Normal endometrium
Endometriosis implants
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 endometriosis implants. CACNA2D3, CBS, and LTBP2 
( Figure 4) immunodetection signal was dramatically 
increased in endometriotic lesions. CACNA2D3 was virtually 
undetectable on normal endometrium sections (Figure 4A 
and B) and presented a high level of expression in endome-
triosis epithelia and smooth muscle cells (Figure 4A′ and B′). 
In the epithelia, CACNA2D3 immunodetection was predomi-
nantly associated to membranes and cytoplasm (arrows in 
Figure 4B′), while CBS and LTBP2 immunodetection (Figure 
4C–D′) was mostly nuclear in endometriosis implants.
Discussion
Morphological and genetic observations on mutant mouse 
uteri and on pathological specimens have prompted the 
suggestion that low DLX5 and DLX6 expressions could be 
associated with the progression of endometriosis. We have 
therefore proposed that Dlx5/6-null mouse uteri could be 
considered as a model of the disease permitting to get new 
insight on this pathology.9
Here, we have compared the gene expression signature 
of Dlx5/6-null mouse uteri with those obtained in four inde-
pendent studies on endometriosis.12–14,20 Dlx5/6-null uteri and 
endometriosis implants share a set of 30 commonly deregu-
lated genes supporting the hypothesis that downregulation of 
Dlx5/6 could be an early event in endometriosis progression. 
The 30 identified genes constitute a more “focused” genetic 
signature of the disease that has permitted potential thera-
peutic targets to be handpicked. We focused, in particular, on 
genes upregulated in endometriosis as they could be potential 
targets for therapeutic strategies.
Table 2 Genes commonly deregulated after Dlx5/6 inactivation in the mouse uterus and in human endometriosis implants
Gene Comparison of normal and 
Dlx5/6-null mouse uterus
Comparison of normal human endometrium  
and endometriosis implants
Log2 fold 
change
P-value Log2 fold 
change 
Hawkins
P-value 
Hawkins
Hever Hull Eyster
Down
DLX5 Absent (targeted deletion) –8,434 1.804E-04 Down Down
NOXA1 –2.25 3.51E-07 –1.816 2.012E-03 Down
DMRTA1 –2.11 2.65E-06 –2.158 2.628E-04
KIAA1324 –2.07 1.96E-07 –19.062 1.180E-05 Down Down Down
SLC27A2 –1.91 1.14E-05 –1.982 5.256E-03 Down Down
GABRP –1.81 5.56E-06 –22.036 2.671E-05 Down
SAPCD2 –1.55 5.04E-04 –2.155 6.115E-03 Down
CENPW –1.36 6.92E-04 –1.905 1.224E-04 Down
PLCH1 –1.32 4.14E-04 –3.082 5.696E-04 Down Down
GJB3 –1.23 2.97E-03 –1.835 5.448E-01 Down
DPP6 –1.21 2.80E-03 –2.917 2.170E-04 Down
OSCP1 –0.95 3.24E-03 –1.714 1.668E-03 Down
JAZF1 -0.88 3.09E-03 –2.719 2.028E-06 Down
Up
CBS 3.09 5.77E-27 2.491 3.844E-03 Up Up
NAIP5 2.44 1.69E-10 1.884 3.807E-04
EMB 1.76 4.38E-08 1.532 5.658E-03
CLIP4 1.52 1.76E-08 2.612 2.198E-04 Up
PIK3AP1 1.48 8.44E-06 2.566 2.857E-03 Up
LAPTM5 1.45 8.85E-05 3.092 7.976E-03 Up Up
CTGF 1.29 3.51E-04 1.582 7.149E-03 Up
NAIP2 1.19 1.04E-03 1.884 3.807E-04
CACNA2D3 1.19 2.61E-03 2.066 2.469E-06 Up
LTBP2 1.14 3.16E-03 4.344 9.850E-05 Up Up Up
TNS3 1.12 1.22E-05 1.583 3.773E-03 Up Up
RAB20 1.08 3.26E-04 1.827 9.691E-03
SYTL2 0.97 1.97E-03 1.788 8.826E-04 Up
LBH 0.97 1.26E-03 2.029 1.615E-03 Up
ENC1 0.91 2.39E-03 2.919 3.286E-03 Up
MANBA 0.83 1.98E-03 2.011 2.363E-03 Up
GALM 0.76 2.27E-03 1.680 1.019E-03 Up
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associated with side effects such as menopausal symptoms 
and reduced bone mineral density,22 which restrict their use 
and demand add-back therapy.23 In addition, pain manage-
ment is one of the major clinical challenges for the treat-
ment of  endometriosis.24 Endometriosis implants, although 
ectopic, are highly innervated. Peritoneal endometriosis 
lesions present a high density of sensory, cholinergic, 
and adrenergic nerve fibers that might be involved in the 
origin of pain.25,26 It has been proposed that a bidirectional 
relation exists between nerve fibers and endometriotic 
lesions with a two-way interaction between the implants 
and the central nervous system.27–29 The interplay between 
the peripheral and the central nervous system might be at 
the origin of individual differences in pain perception that 
can, in some patients, evolve independently from the dis-
ease.30 When pathological conditions cause damage to the 
nervous system, sensory activation thresholds are lowered 
with exaggerated pain perception even upon mild or absent 
painful stimulation.
Figure 2 Molecular signature of endometriosis obtained comparing genes 
deregulated in Dlx5/6 mutant mice uteri and in endometriosis lesions.
Molecular signature of endometriosis
229 down 13 down 997 down
1086 up17 up195 up
Bellessort et al (2016)9 Hawkins et al (2011)12
Figure 3 (Continued)
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Current endometriosis therapies present limited effi-
cacy, high rates of symptom recurrence, and significant 
side effects.3,4 For example, the use of GnRH agonists is 
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Between the 17 upregulated gene candidates, we 
focused specifically on CACNA2D3, member of the family 
of α2δ VGCC subunits involved in nociception (Figure 5). 
CACNA2D1, CACNA2D2, CACNA2D3, and CACNA2D4 
constitute the α2δ family of VGCC subunits.16 VGCC 
are composed of α1 subunit proteins involved in pore 
formation31 and many possible splice variants of the α1, 
β, and α2δ subunits. Such a molecular diversity confers 
to these channels a variety of specific properties in differ-
ent cell types and situations. VGCCs play a critical role 
in neuropathic pain development through the modulation 
of the release of excitatory neurotransmitters,32 calcium-
dependent enzyme activation,33 gene regulation,33–35 and 
short- and long-term plasticity changes.36–39 Abnormal 
regulation of VGCC subunits, such as α2δs, may contribute 
to pain signal transduction through several mechanisms 
including the induction of abnormal synaptogenesis.40,41 
Dysregulation of VGCCs and their subunits has been 
observed in pathological conditions, including nerve inju-
ries and animal models of endometriosis;42 it is therefore 
possible that these channels contribute to the origin of 
endometriosis-associated pain.
Gabapentinoids, including gabapentin (Neurontin; Pfizer, 
Zürich, CH) and pregabalin (Lyrica; Pfizer), are compounds 
used for the treatment of neuropathic pain.43,44 As seen by 
binding of [3H]gabapentin to membranes from COS-7 cells 
transfected with α2δ cDNA, gabapentinoids bind predomi-
nantly to α2δ1, α2δ2 subunits of VGCCs.45–47 However, an 
evolutionary conserved role in nociception has also been 
shown for α2δ3, and SNP variants of this subunit are associ-
ated with reduced sensitivity to heat and chronic back pain.15
Conclusion
Analgesics, such as nonsteroidal anti-inflammatory drugs 
(NSAIDs) and gabapentin, are often used for pain relief 
despite limited evidence of their efficacy in  endometriosis.4,48 
Figure 3 qPCR validation of genes upregulated after Dlx5/6 invalidation in the mouse uterus.
Notes: (A) Relative mRNA expression in normal (black) and mutant (white bars) mouse uteri of upregulated genes belonging to our newly identified endometriosis 
signature. Reference gene: Sdha. *P<0.05, **P<0.01, Mann and Whitney test analysis. Each group was constituted by five independent samples. (B) Relative mRNA expression 
in normal (black) and mutant (white bars) mouse uteri of downregulated genes identified as commonly deregulated genes belonging to our newly identified endometriosis 
signature (as shown in Table 2). Reference gene: Sdha. *P<0.05, **P<0.01, Mann and Whitney test analysis. Each group was constituted by five independent samples.
Abbreviation: qPCR, quantitative real-time PCR.
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A recent pilot trial on 47 patients49 and several clinical 
 observations48,50 have suggested that treatment with gaba-
pentin alleviates significantly endometriotic pain;  however, 
given the small size of the trials, uncertainty remains.43 Our 
findings provide evidence supporting a definitive evalu-
ation of the efficacy of gabapentin in the management of 
endometriosis-associated pain.
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Figure 4 Immunolocalization of CACNA2D3, CBS, and LTBP2 in normal 
endometrium and in ovarian endometriosis implants.
Notes: Immunolocalization of CACNA2D3, CBS, and LTBP2 on sections from 
normal endometrium (A–C) and from endometriosis implants (A′, B′, and C′). 
Arrows indicate CACNA2D3 distribution in epithelial cells of endometriosis 
implants. Scale bar: (A, A′, C, C′, D, and D′) 250 µm and (B and B′) 62.5 µm.
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Figure 5 Summary diagram.
Note: The reduction of DLX5 expression in endometriosis implants results in an increased expression of α2δ subunits with a potential increase in neuropathic nociception.
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